How Staph bacteria damage the skin and spark allergies
Staphylococcal protease-mediated epithelial barrier perturbation and allergen sensitization
This work looks at whether enzymes made by Staphylococcus aureus break down the skin’s protective barrier and lead to allergic skin problems like atopic dermatitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11228786 on NIH RePORTER |
What this research studies
If you have eczema or sensitive skin, researchers will examine how Staphylococcus aureus on the skin produces a protease (an enzyme) that may weaken the skin barrier and let allergens get through. They will use laboratory models and tissue samples to track how this enzyme changes skin cell behavior and how those changes signal to immune cells and nearby nerves. The team will map gene activity in barrier-disrupted skin and test how bacterial proteolytic activity influences the development of allergic sensitization. The aim is to identify specific bacterial-driven steps that could be targeted to protect the skin and prevent allergic inflammation.
Who could benefit from this research
Good fit: People with atopic dermatitis (eczema), frequent skin flares, or known Staphylococcus aureus skin colonization would be most relevant to this work.
Not a fit: Individuals with non-allergic skin conditions or allergic problems that do not involve the skin barrier or Staphylococcus colonization are less likely to benefit directly from these findings.
Why it matters
Potential benefit: If successful, this could point to new ways to prevent or treat atopic dermatitis by blocking harmful bacterial enzymes or strengthening the skin barrier.
How similar studies have performed: Previous research has linked Staphylococcus aureus colonization to worse eczema and preclinical work suggests bacterial proteases can damage skin, but translating these findings into human treatments remains limited.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Park, Jin Mo — Massachusetts General Hospital
- Study coordinator: Park, Jin Mo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.